Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Neurosigma Announces Fda Clearance Of Monarch Etns System As First Non-drug Treatment For Pediatric Adhd
LPNEWS

Neurosigma Announces Fda Clearance Of Monarch Etns System As First Non-drug Treatment For Pediatric Adhd

by prnewswire.com posted 3months ago 158 views
LOS ANGELES, April 23, 2019 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders today announced that its Monarch® eTNS® System...

In this article